LGND News and Press, Ligand Pharmaceuticals Incorporated From 10/21/22

COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional findings from its Evaluation...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separat...

Summary Ligand Pharmaceuticals is an intriguing but complicated business. The company employs multiple business lines and models under a roof, and at times makes transformative alternations to its business. Fundamental earnings power is fairly limited here, leaving many questi...

Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s lead investigational drug COLUMBUS, Ohio, Sept. 14, 2022 (GLOBE NEW...

Sermonix Pharmaceuticals said lasofoxifene showed anti-tumor activity but could not reach statistical significance in a phase 2 trial in patients with a type of breast cancer. Privately held Sermonix had licensed lasofoxifene — a nonsteroidal selective estrogen recep...

COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced results of its signal-seeking E...

First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc...

Ligand Pharmaceuticals, Inc. (LGND) Q2 2022 Earnings Conference Call August 08, 2022, 16:30 ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Korenberg - EVP, Finance & CFO Matthew Foehr - President &...

Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q2 Non-GAAP EPS of $1.03 beats by $0.60 . Revenue of $57.4M (-32.2% Y/Y) beats by $19.67M . Raises FY 2022 Guidance: Ligand is raising 2022 revenue guidance for the combined business and is reaffirming ...

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and progr...